Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 1

Conditions

Melanoma 3Neoplasm Metastasis 2Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × omaveloxolone × Dermatologic × Clear all
NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

Biogen

Phase 1/2 Completed
41 enrolled 15 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT03593499 2025-05-31

Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401

Biogen

No longer available
Dermatologic

Melanoma

NCT02029729 2025-05-29

DISCOVER

Biogen

Phase 1 Completed
11 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡